As per the research report, the size of the Asia Pacific Microbiology Testing/Clinical Microbiology Market is valued at USD 0.78 billion in 2022 and is predicted to be growing at a CAGR of 11.45%, touching USD 1.34 billion by 2027 during the forecast period 2022 to 2027.
Infectious illness outbreaks are rising, and technological improvements are propelling the Asia Pacific clinical microbiology market forward.
Early identification of the infection is becoming more popular as people become more aware of the dangers of infection. It is accelerating the expansion of the microbiology testing market. As infectious diseases spread across the Asia Pacific, the government and non-governmental groups support innovative technology in clinical microbiology.
In clinical microbiology, many rapid assays are used to detect specific microbial antigens or nucleic acids in primary non-tissue specimens, which helps identify infections much faster in severe cases. It is fueling the market's expansion. Clinical microbiology technology has advanced significantly since it demands an accurate and reliable approach to identifying clinically significant microorganisms, driving the market growth. In recent years, many microbiological laboratories have adopted automation to process isolation and detect a specific microorganism.
The study of microorganisms that cause human infection is known as clinical microbiology. According to the Centers for Disease Control & Prevention, the number of visits to physician offices with infectious and parasitic disorders as the significant diagnosis was 16 million in 2018. The market for microbiology testing/clinical microbiology is growing at a reasonable rate due to the COVID-19 epidemic.
Because pathogenic microbes must be handled, clinical microbiology necessitates a well-trained and skilled team. The test equipment is expensive and difficult to use, which is expected to hamper the growth of the worldwide microbiology testing or clinical microbiology market. The rise in real-time technical hurdles is also stifling market demand. The government's stringent approval procedures for new items are also expected to hamper the market's growth.
The entire world has been placed on high alert due to the novel coronavirus pandemic. This pandemic has already impacted the clinical microbiology industry. Manufacturing and supply chain issues, such as timely delivery of items to end-users, are difficult for the sector. In addition, the supply of clinical microbiology products to end-users has been curtailed due to a shortage of competent lab personnel to conduct diagnostic tests, limited support for research and development, and lockdowns.
This research report on the APAC Microbiology Testing/Clinical Microbiology Market has been segmented and sub-segmented into the following categories.
By Microbiology Application:
By Clinical Application:
Geographically, Asia-Pacific is predicted to grow faster than the rest of the world throughout the projection period due to an expansion in hospitals and clinical diagnostic laboratories and increased research capability to develop new and cost-effective clinical and microbiological testing techniques.
The India Microbiology Testing Market is expected to have the highest market growth in the region due to an increase in the senior population, an increase in the number of clinical research studies in the field of clinical microbiology, rising rates of infectious diseases, and increased financing, research grants, and public-private partnerships.
The China Microbiology Testing Market is predicted to be the market leader in Asia Pacific Microbiology Testing throughout the forecast period due to an increase in the number of hospitals and testing laboratories and increasing research and development and innovative microbiological testing procedures.
KEY MARKET PLAYERS
Top companies dominating the APAC Microbiology Testing/Clinical Microbiology Market profiled in the report are Danaher Corporation (U.S.), Alere Inc. (U.S.), Bruker Corporation (U.S.), and Hologic, Inc. (U.S.), Becton, Dickinson, and Company (U.S.), Bio-Rad Laboratories Inc. (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Cepheid (U.S.) Abbott Laboratories Inc.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com